The European Food Safety Authority (EFSA) first assessed the health risk of primary products for smoke flavourings between 2007 and 2012 in the context of an authorisation procedure. None of the primary products assessed exceeded the maximum levels for benzo[a]pyrene and benzo[a]anthracene of 10 and 20 micrograms (μg) per kilogramme (kg) of primary product. These substances belong to the group of polycyclic aromatic hydrocarbons (PAHs), several of which (e.g. benzo[a]pyrene) can damage the genome and cause cancer. The concentrations of twelve other PAHs measured were in most cases below - or only just above - the respective limits of detection. The ten currently authorised primary products proved to be genotoxic in bacterial gene mutation tests and/or in tests on mammalian cell cultures. However, this was not confirmed in animal studies. Therefore, there were no concerns regarding the genotoxic potential of the primary products at that time.
However, at that time, EFSA came to the conclusion that the intake levels for most primary products were too high under the conditions of use envisaged in the application documents. They should therefore be used in lower quantities or in fewer food groups than proposed by the applicants.
Ten primary products were subsequently authorised for ten years (until 1 January 2024), which has been extended for the time being by six months for formal reasons. The draft Implementing Regulation No. 1321/2013 on smoke flavourings was adopted by a qualified majority of the EU Member States on 21 October 2013. When using the ten primary products approved since the Implementing Regulation came into force on 1 January 2014 at the maximum permitted levels, the margin of safety between the amount of primary products ingested with food and the highest dose at which no adverse effects occurred in the animal study on subchronic toxicity was lower than recommended by the EFSA and the BfR for seven of the ten approved primary products. The level of protection for these primary products was therefore lower than recommended. Germany therefore did not support the draft regulation at the time, taking into account an opinion from the BfR.
In 2023, eight of the authorised primary products were reassessed by the EFSA after their manufacturers submitted applications to the European Commission to extend the authorisation granted in 2013. In accordance with Regulation (EC) No. 2065/2003, new applications and new risk assessments by EFSA were required to extend the authorisation for a further ten years. The applicants submitted new data for this purpose.
Based on the available data, EFSA has now come to the conclusion that none of the eight smoke flavouring primary products assessed can be considered safe for human health.
EFSA's rationale is that six of the eight primary products assessed raise health concerns with regard to their genotoxic potential because they contain furan-2(5H)-on. The compound has been shown to be genotoxic in vivo. In addition, four of these primary products contain 1,2-dihydroxybenzene (synonym: catechol, pyrocatechol), which is also genotoxic in vivo. There are indications of genotoxic potential for the other two smoke flavouring primary products, which still need to be clarified experimentally. In addition, furan-2(5H)-on was not identified in one of these two primary products with the (inadequate) analytical methods used, but the absence of this substance was not convincingly demonstrated.
The European Food Safety Authority (EFSA) first assessed the health risk of primary products for smoke flavourings between 2007 and 2012 in the context of an authorisation procedure. None of the primary products assessed exceeded the maximum levels for benzo[a]pyrene and benzo[a]anthracene of 10 and 20 micrograms (μg) per kilogramme (kg) of primary product. These substances belong to the group of polycyclic aromatic hydrocarbons (PAHs), several of which (e.g. benzo[a]pyrene) can damage the genome and cause cancer. The concentrations of twelve other PAHs measured were in most cases below - or only just above - the respective limits of detection. The ten currently authorised primary products proved to be genotoxic in bacterial gene mutation tests and/or in tests on mammalian cell cultures. However, this was not confirmed in animal studies. Therefore, there were no concerns regarding the genotoxic potential of the primary products at that time.
However, at that time, EFSA came to the conclusion that the intake levels for most primary products were too high under the conditions of use envisaged in the application documents. They should therefore be used in lower quantities or in fewer food groups than proposed by the applicants.
Ten primary products were subsequently authorised for ten years (until 1 January 2024), which has been extended for the time being by six months for formal reasons. The draft Implementing Regulation No. 1321/2013 on smoke flavourings was adopted by a qualified majority of the EU Member States on 21 October 2013. When using the ten primary products approved since the Implementing Regulation came into force on 1 January 2014 at the maximum permitted levels, the margin of safety between the amount of primary products ingested with food and the highest dose at which no adverse effects occurred in the animal study on subchronic toxicity was lower than recommended by the EFSA and the BfR for seven of the ten approved primary products. The level of protection for these primary products was therefore lower than recommended. Germany therefore did not support the draft regulation at the time, taking into account an opinion from the BfR.
In 2023, eight of the authorised primary products were reassessed by the EFSA after their manufacturers submitted applications to the European Commission to extend the authorisation granted in 2013. In accordance with Regulation (EC) No. 2065/2003, new applications and new risk assessments by EFSA were required to extend the authorisation for a further ten years. The applicants submitted new data for this purpose.
Based on the available data, EFSA has now come to the conclusion that none of the eight smoke flavouring primary products assessed can be considered safe for human health.
EFSA's rationale is that six of the eight primary products assessed raise health concerns with regard to their genotoxic potential because they contain furan-2(5H)-on. The compound has been shown to be genotoxic in vivo. In addition, four of these primary products contain 1,2-dihydroxybenzene (synonym: catechol, pyrocatechol), which is also genotoxic in vivo. There are indications of genotoxic potential for the other two smoke flavouring primary products, which still need to be clarified experimentally. In addition, furan-2(5H)-on was not identified in one of these two primary products with the (inadequate) analytical methods used, but the absence of this substance was not convincingly demonstrated.